656 related articles for article (PubMed ID: 21221766)
21. A long-term survival pattern for breast cancer treated in a single institution.
Gokce T; Karadogan I; Akcay C
Indian J Cancer; 2011; 48(2):187-93. PubMed ID: 21768664
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
23. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
24. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Torrisi R; Bagnardi V; Cardillo A; Bertolini F; Scarano E; Orlando L; Mancuso P; Luini A; Calleri A; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2008 Nov; 99(10):1564-71. PubMed ID: 18941458
[TBL] [Abstract][Full Text] [Related]
25. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
27. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
[TBL] [Abstract][Full Text] [Related]
30. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
31. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
32. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
33. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
34. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?
Aurilio G; Bagnardi V; Graffeo R; Nolè F; Petit JY; Locatelli M; Martella S; Iera M; Rey P; Curigliano G; Rotmensz N; Munzone E; Goldhirsch A
Anticancer Res; 2014 Nov; 34(11):6677-83. PubMed ID: 25368274
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
Gogas H; Pectasides D; Kostopoulos I; Lianos E; Skarlos D; Papaxoinis G; Bobos M; Kalofonos HP; Petraki K; Pavlakis K; Bafaloukos D; Fountzilas G
Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
38. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
39. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Barbie TU; Ma C; Margenthaler JA
Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
[TBL] [Abstract][Full Text] [Related]
40. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]